pharmaphorum.com
Lilly's GLP-1s race away in Q2, though Foundayo falls short
Eli Lilly has posted another record quarter of revenue growth, up 48% to $23bn, with Mounjaro and Zepbound now making up two-thirds of the total.
#Zepbound is an active hashtag on Bluesky. In the last 30 days, 14 people shared 17 posts with it — around 1 a day. Activity is up 67% versus the previous week, peaking on Jul 23 with 3 posts.
pharmaphorum.com
Lilly's GLP-1s race away in Q2, though Foundayo falls short
Eli Lilly has posted another record quarter of revenue growth, up 48% to $23bn, with Mounjaro and Zepbound now making up two-thirds of the total.
third-news.com
Eli Lilly Records Impressive Q2 2026 Earnings, Boosts Annual Forecast Amid Strong Drug Sales
Eli Lilly's second-quarter 2026 report showcases remarkable growth with a 48% revenue increase, driven by successful drugs and an elevated annual outlook.
www.forbes.com
Health Canada Approves Weight-Loss Drug For Sleep Apnea In Patients With Obesity
Health Canada approved the weight-loss drug Zepbound for the treatment of obstructive sleep apnea in adults living with obesity.
surveymoh.health.gov.bc.ca
Tirzepatide (Zepbound®) for Moderate to Severe Obstructive Sleep Apnea (OSA) in Adults with Obesity, Without Diabetes | Ministry of Health
pharmaphorum.com
Novo sues Lilly over 'misleading' GLP-1 ad campaigning
The rivalry between Novo Nordisk and Eli Lilly in the GLP-1 market has spilled over into the courts in the US, with claims of misleading advertising.
www.tv2ostjylland.dk
Vægttabsmedicin kan øge risikoen for hårtab
Det kan øge risikoen for at tabe håret, hvis man indtager hormonet GLP-1, der findes i Novo Nordisks og Eli Lillys diabetes- og vægttabsprodukter, Wegovy og Zepbound. Risikoen for hårtab er fortsat lav, men den er højere end ved indtagelse af andre typer diabetesmedicin. Det skriver Reuters, der henviser til et ny...
www.indyturk.com
İki zayıflama iğnesi üreticisi hukuk mücadelesine girdi
Danimarkalı ilaç şirketi Novo Nordisk, kilo verme tedavilerinin etkinliği konusunda yanıltıcı reklamlar yaptığı iddiasıyla ABD'li rakibi Eli Lilly'ye salı günü New Jersey'deki bir federal mahkemede dava açtı. Dava, Indianapolis merkezli Eli Lilly'nin obezite ilacı Zepbound ve diyabet ilacı Mounjaro için ülke çapında yürüttüğü tanıtım kampanyalarıyla federal ve eyalet yasalarını ihlal ettiğini öne sürüyor. fazla oku Bu bölüm, konuyla ilgili referans noktalarını içerir.
statnews.com
Novo Nordisk sues Eli Lilly over GLP-1 drug ads it calls ‘deceptive’
Novo Nordisk sued Eli Lilly for allegedly running a “deceptive” ad campaign that uses “outdated clinical trials” to make its obesity and diabetes drugs appear more effective.
Posts are pulled live from Bluesky and cached briefly. Posts with content labels are hidden.